All In Biotech

Drug Trial Radar · NCT07421232

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Dec 3, 2024

Primary completion

Aug 30, 2025

Study completion Feb 12, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled

Conditions

  • Hypercholesterolemia and Mixed Hyperlipidemia

Interventions

  • SYH2053/placebo injectionDrug

    Participants receive SYH2053/placebo injection by subcutaneous administration.

  • Inclisiran (Leqvio®) 300mgDrug

    Participants receive Leqvio® injection by subcutaneous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in LDL-C relative to baselineTime frame: Day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliation: Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.